Association of class II and III BRAF mutations with EGFR blockade therapy response and representation of molecularly distinct subgroups of BRAF mutations in MMR proficient CRC


Ibrahim Halil Sahin, Joanne Xiu, Moh’d M. Khushman, Emily Palumbo, Benjamin Adam Weinberg, Sanjay Goel, Aatur Singhi, Phoenix D Bell, Emil Lou, Anup Kasi, Anthony F. Shields, Matthew James Oberley, George W. Sledge Jr., John Paul Shen, Anwaar Saeed, Mohammedtaki Tejani

Key Finding:

  • In a study of 18,575 MMR-proficient colorectal cancers, Class II and III BRAF mutants were more likely to be seen in younger patients with improved outcomes from EGFR blockade.
Download Publication